Insights into the treatment of infliximab and vedolizumab in positive PR3-ANCA patients with moderately to severely active ulcerative colitis: multicenter real-world evidence.
Sign Up to like & getrecommendations! Published in 2025 at "BMC gastroenterology"
DOI: 10.1186/s12876-025-04372-2
Abstract: Perinuclear anti-neutrophil cytoplasmic antibody(p-ANCA) positivity may indicate poor response to infliximab (IFX) in ulcerative colitis (UC). Nevertheless, there has been limited research on the effect of proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) in UC patients… read more here.
Keywords: anca; anca patients; positive pr3; ulcerative colitis ... See more keywords